angiotensin receptor blocker

By Targets:	Angiotensin Receptor (10) Acyltransferase (1) Apoptosis (1) Arrestin (3) Bacterial (1) Isotope-Labeled Compounds (1) PPAR (2) SARS-CoV (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (11) Endocrinology (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (2)

Targets Recommended: Angiotensin Receptor Angiotensin-converting Enzyme (ACE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138067

SSAA09E2	SARS-CoV	Inflammation/Immunology
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .

HY-111032

Allisartan isoproxil	Angiotensin Receptor	Cardiovascular Disease
Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1. Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs .

HY-160292

Enoltasosartan

Angiotensin Receptor Cardiovascular Disease

Enoltasosartan is an angiotensin II (AngII) receptor blocker .

Enoltasosartan	Angiotensin Receptor	Cardiovascular Disease
Enoltasosartan is an **angiotensin II (AngII) receptor** blocker .

HY-19022

BW A256C	Others	Cardiovascular Disease Others Metabolic Disease
Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties .

HY-106123

Pomisartan	Angiotensin Receptor	Cardiovascular Disease
Pomisartan is an orally active angiotensin II receptor type AT1 antagonist (IC₅₀=0.26 μM). Pomisartan works by inhibiting the binding of angiotensin II to the AT1 receptor, thereby blocking the vasoconstriction and aldosterone release caused by this interaction. Pomisartan results in a blood pressure-lowering effect .

HY-B0205

Candesartan 4 Publications Verification CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active **angiotensin II AT1-Receptor** blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-12765

Losartan Carboxylic Acid E-3174; EXP-3174	Angiotensin Receptor	Cardiovascular Disease
Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active **angiotensin II AT1-Receptor** blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-12765S1

Losartan carboxylic acid-d4 hydrochloride	Isotope-Labeled Compounds Angiotensin Receptor	Cardiovascular Disease
Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ß-arrestins while blocking* G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141

TRV-120027 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ß-arrestins while blocking* G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-119706

Barbadin Maximum Cited Publications 10 Publications Verification	Apoptosis Arrestin	Others
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC₅₀ values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .

HY-N9530

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone	Acyltransferase Angiotensin Receptor Bacterial	Infection Cardiovascular Disease Metabolic Disease
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and **angiotensin II receptor** blocker, with IC₅₀s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library	493 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 493 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

493 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 493 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Target	Research Area

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ß-arrestins while blocking* G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141

TRV-120027 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ß-arrestins while blocking* G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9530

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone	Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields	Acyltransferase Angiotensin Receptor Bacterial
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and **angiotensin II receptor** blocker, with IC₅₀s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .

Cat. No.	Product Name	Chemical Structure

HY-12765S1

Losartan carboxylic acid-d4 hydrochloride
Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].

Losartan carboxylic acid-d4 hydrochloride

Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds